ArticleJournal of bone oncology2026
Dual-target neoadjuvant therapy with denosumab and sunitinib for giant cell tumor of bone: a sarcoma center experience.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Giant cell tumor of bone (GCTB) is a locally aggressive tumor characterized by osteoclast-like giant cells and neoplastic stromal cells. While denosumab effectively targets giant cells, stromal cells may persist and drive recurrence. This study evaluates the efficacy and safety of a novel neoadjuvant regimen combining denosumab with sunitinib, a tyrosine kinase inhibitor targeting stromal cell signaling. To our knowledge, this represents the first clinical series evaluating a novel neoadjuvant regimen combining denosumab with sunitinib in GCTB. Methods: We conducted a retrospective case series of 16 patients with histologically confirmed Campanacci grade 3 (or grade 2 in anatomically challenging locations) GCTB treated at a tertiary sarcoma center between January 2019 and September 2024. All patients received neoadjuvant denosumab and sunitinib prior to definitive surgery. Surgical outcomes, local recurrence, histopathological tumor regression, disease-free survival, and the relative tyrosine phosphorylation levels were analyzed. Results: Of the 16 patients (mean age 28.7 years), most had Campanacci grade 3 lesions (87.5%). En-bloc resection was performed in 43.8% and curettage in 50% of cases. Histological analysis showed near-complete regression of giant cells (mean 99.7%) and partial regression of stromal cells (mean 62.8%). Two patients (12.5%) experienced local recurrence. Disease-free survival at two years was 80%. Treatment was well tolerated, with no unexpected adverse events or dose-limiting toxicities. Conclusion: Neoadjuvant combination therapy with denosumab and sunitinib was feasible and well tolerated and resulted in substantial histological regression of both giant cells and neoplastic stromal cells. While recurrence outcomes in this limited cohort remain descriptive, the observed stromal suppression and RTK signaling profiles support the biological rationale for dual-targeted therapy. These findings justify further prospective investigation, particularly in aggressive or surgically challenging GCTB cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.